|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 2
|
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
|
|
Dec 31
|
Top Midday Decliners
|
|
Dec 31
|
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership
|
|
Dec 31
|
Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations
|
|
Dec 31
|
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future
|
|
Dec 31
|
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
|
|
Dec 31
|
SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse
|
|
Dec 31
|
Sangamo stock plummets 50% after Pfizer ends gene therapy deal
|
|
Dec 31
|
Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug
|
|
Dec 31
|
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
|
|
Dec 31
|
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership
|
|
Dec 31
|
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal
|
|
Dec 31
|
Trending tickers: Tesla, Bitcoin, Sangamo, Endeavour
|
|
Dec 31
|
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
|
|
Dec 30
|
Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
|
|
Dec 30
|
Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?
|